» Articles » PMID: 20145007

Low-valency, but Not Monovalent, Antigens Trigger the B-cell Antigen Receptor (BCR)

Overview
Journal Int Immunol
Date 2010 Feb 11
PMID 20145007
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Antigen binding to the B-cell antigen receptor (BCR) leads to receptor triggering and B-lymphocyte activation. Here, we have probed the molecular requirements for BCR triggering in primary murine B cells using a set of defined soluble haptenated peptides. Bi- and trivalent haptens activated the BCR, as measured by protein phosphorylation, Ca(2+) influx, BCR down-modulation and CD69, CD86 and MHC class II up-regulation. In contrast, four distinct monovalent haptens were ineffective. Next, we used two different anti-idiotypic antibodies, which bind to the antigen-combining site of the BCR. Again, monovalent Fab fragments were ineffective, whereas bivalent antibodies could stimulate the BCR. These findings are compatible with ligand-induced clustering of monomeric BCRs or re-organization of BCR complexes within pre-formed BCR oligomers. Lastly, an increase in the valency of the haptenated peptides improved the activation potential, whereas variations in the distance between two haptens had no effect. This finding contributes to understand how the immune system can efficiently recognize structurally diverse antigens but still discriminate between foreign and self.

Citing Articles

Dynamics and activation of membrane-bound B cell receptor assembly.

Do H, Zhao M, Alam S, Gnanakaran S Commun Biol. 2025; 8(1):226.

PMID: 39948415 PMC: 11825855. DOI: 10.1038/s42003-025-07478-1.


Engineered protein subunit COVID19 vaccine is as immunogenic as nanoparticles in mouse and hamster models.

Matthews M, Kim T, Kim K, Meshcheryakov V, Iha H, Tamai M Sci Rep. 2024; 14(1):25528.

PMID: 39462119 PMC: 11512993. DOI: 10.1038/s41598-024-76377-y.


Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice.

Tong K, Hernandez E, Basore K, Fremont D, Lai J Vaccine. 2024; 42(26):126405.

PMID: 39413488 PMC: 11645211. DOI: 10.1016/j.vaccine.2024.126405.


Towards a unifying model for B-cell receptor triggering.

Degn S, Tolar P Nat Rev Immunol. 2024; 25(2):77-91.

PMID: 39256626 DOI: 10.1038/s41577-024-01073-x.


Both sides now: evolutionary traits of antigens and B cells in tolerance and activation.

Hong Y, Kwak K Front Immunol. 2024; 15:1456220.

PMID: 39185403 PMC: 11341355. DOI: 10.3389/fimmu.2024.1456220.